TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23496265

Group type: EXPERIMENTAL
Intervention: Combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maximum dose of losartan (100 mg)
Number of subjects: 0
Study: 20833549

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery TKA (MIS group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional TKA (conventional group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (MIS and conventional)
Number of subjects: 30
Study: 19457937

Group type: EXPERIMENTAL
Intervention: ITP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2, paclitaxel 175 mg/m² on day 1)
Number of subjects: 153

Group type: COMPARATOR
Intervention: IP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: ITP regimen
Number of subjects: 153

Group type: COMPARATOR
Intervention: IP regimen
Number of subjects: 153
Study: 16393594

Group type: EXPERIMENTAL
Intervention: Single one‐pass pulsed dye laser treatment (595 nm, 7 J/cm2 fluence, 7 mm spot size, 1.5‐millisecond pulse duration, 30‐millisecond spray, 20‐millisecond delay of dynamic cooling) at the time of suture removal (2 weeks after excision)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment with laser)
Number of subjects: 20
Study: 14680672

Group type: EXPERIMENTAL
Intervention: Claims-based feedback about patterns of HbA1C measurement, educational materials, and practice aids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study: 10728742

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 9175692

Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy with bilateral salpingo‐oophorectomy (N=91)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Hysterectomy (abdominal or vaginal) only or hysterectomy with unilateral salpingo‐oophorectomy (N=73)
Number of subjects: 164
Study: 1413555

Group type: EXPERIMENTAL
Intervention: Isoluminant stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equivalent luminance contrast stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmasked stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimuli embedded in luminance noise
Number of subjects: 0
Study: 3158674

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg bid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Metoprolol 100 mg bid
Number of subjects: 18
Study: 29333721

Group type: EXPERIMENTAL
Intervention: 60 g·h‐1 (LG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 g·h‐1 (HG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 90 g·h‐1 (LGF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 112.5 g·h‐1 (HGF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 90 g·h‐1 glucose-fructose ingestion
Number of subjects: 10
Study: 27388860

Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online self-study module
Number of subjects: 0
Study: 25372911

Group type: EXPERIMENTAL
Intervention: Superior transseptal approach (n=47)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional left atriotomy (n=44)
Number of subjects: 91
Study: 24092691

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20052587

Group type: EXPERIMENTAL
Intervention: Ribosomal prophylaxis
Number of subjects: 60
Study: 17574461

Group type: EXPERIMENTAL
Intervention: Zonisamide (mean maintenance dosage 7.7 mg/kg/day, range: 4-16 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 24
Study: 16364497

Group type: EXPERIMENTAL
Intervention: Dynamic visual noise (visuo-spatial interference)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition (blank computer screen)
Number of subjects: 42
Study: 12502672

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10190650

Group type: EXPERIMENTAL
Intervention: Salbutamol (beta2-adrenoceptor partial agonist)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 17

Group type: COMPARATOR
Intervention: ICI 118,551 (beta2-adrenoceptor antagonist)
Number of subjects: 17

Group type: COMPARATOR
Intervention: ICI 118,551
Number of subjects: 17
Study: 7672550

Group type: EXPERIMENTAL
Intervention: Disposable, sheathed, flexible sigmoidoscope
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard sigmoidoscope
Number of subjects: 143
Study: 1979207

Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7013943

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 31232970

Group type: EXPERIMENTAL
Intervention: Curettage and bone grafting combined with elastic intramedullary nailing (EIN)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Curettage and bone grafting alone (non-elastic intramedullary nailing - NEIN)
Number of subjects: 62
Study: 28592029

Group type: EXPERIMENTAL
Intervention: Noninvasive proportional assist ventilation (PAV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noninvasive pressure support ventilation (PSV)
Number of subjects: 10
Study: 25734733

Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam
Number of subjects: 1062

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study: 23380515

Group type: EXPERIMENTAL
Intervention: High tidal volume (Hi-TV) of 10 mL/kg, rate of 7 breaths/min, zero positive end-expiratory pressure
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low tidal volume (Lo-TV) of 5 mL/kg, rate of 14 breaths/min, 5 cmH2O positive end-expiratory pressure
Number of subjects: 34
Study: 21317598

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment integrated with HIV care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing communication and technical assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive evaluation design
Number of subjects: 0
Study: 19270469

Group type: EXPERIMENTAL
Intervention: Emotional disclosure intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Time management sessions
Number of subjects: 68
Study: 17024925

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 0
Study: 12885711

Group type: EXPERIMENTAL
Intervention: 3 months exclusive breastfeeding
Number of subjects: 3483

Group type: COMPARATOR
Intervention: 6 months exclusive breastfeeding
Number of subjects: 3483
Study: 11605710

Group type: EXPERIMENTAL
Intervention: Anthroposophic therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional cancer treatment
Number of subjects: 120
Study: 9526967

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDP, Librium) 5 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDP, Librium) 20 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7510813

Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micrograms/kg per day by 30-min infusion for 28 days or until neutrophil recovery
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 2530384

Group type: EXPERIMENTAL
Intervention: h-alpha ANP infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle (Ve)
Number of subjects: 7
Study: 1234013

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (300 mug cumulative dose in three injections over 45 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aerosol salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 10
Study: 6795701

Group type: EXPERIMENTAL
Intervention: 5‐FU‐carmustine
Number of subjects: 109

Group type: COMPARATOR
Intervention: ftorafur‐carmustine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Higher dosage of ftorafur (2 g/m2/day X 5 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 5‐FU combination chemotherapy
Number of subjects: 109
Study: 30857189

Group type: EXPERIMENTAL
Intervention: Intervention group (SHHC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29346597

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice a day for 12 weeks
Number of subjects: 24
Study: 26590293

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study: 24290606

Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d) and kinako (29.14 g/d)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Kinako (29.14 g/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fish oil (3 g/d)
Number of subjects: 65
Study: 23662522

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (sevoflurane)
Number of subjects: 60
Study: 20680907

Group type: EXPERIMENTAL
Intervention: Conventional posterolateral thoracotomy (Group I, n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Muscle-sparing posterolateral thoracotomy (Group II, n=25)
Number of subjects: 50
Study: 17625977

Group type: EXPERIMENTAL
Intervention: 10% solution of 15 g fructose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10% solution of 25 g fructose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10% solution of 50 g fructose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 33% solution of 50 g fructose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of doses
Number of subjects: 20
Study: 15989703

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) at 250 mg/m2 per day, starting 24 hours after completion of chemotherapy and continuing up to 48 hours before the next cycle.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide combination treatment.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) arm.
Number of subjects: 34
Study: 11875707

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Cyclin A overexpression
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Neu overexpression
Number of subjects: 394
Study: 9833957

Group type: EXPERIMENTAL
Intervention: Nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nucleoside therapy alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 29
Study: 7621844

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: carteolol
Number of subjects: 78

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 78

Group type: COMPARATOR
Intervention: arotinolol
Number of subjects: 78

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 78
Study: 2143062

Group type: EXPERIMENTAL
Intervention: 6-week structured psychiatric group intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 35
Study: 353969

Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg daily before bedtime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 40
Study: 28951440

Group type: EXPERIMENTAL
Intervention: PYD-based sports mentorship program for 18 weeks, 90 minutes per session
Number of subjects: 664

Group type: COMPARATOR
Intervention: Health education website (control)
Number of subjects: 664
Study: 26447155

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1.8 g/d for 4 weeks
Number of subjects: 82
Study: 24093344

Group type: EXPERIMENTAL
Intervention: Take-Wait-Stop label
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard label
Number of subjects: 0
Study: 21812266

Group type: EXPERIMENTAL
Intervention: Qumin Tongbi Nasal Spraying Agent (QTNSA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Veconase (Control)
Number of subjects: 103
Study: 19708910

Group type: EXPERIMENTAL
Intervention: STORZ DCI video laryngoscope (VL)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard direct laryngoscopy (DL)
Number of subjects: 56
Study: 17976096

Group type: EXPERIMENTAL
Intervention: Physiologic pacing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-paced children
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All children
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All children with CCAVB
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Children with DCM
Number of subjects: 36
Study: 15114905

Group type: EXPERIMENTAL
Intervention: Keyword method with keywords and images generated by the experimenter
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Keyword method with keywords and images generated by themselves
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Keyword method with keywords and images previously generated by peers
Number of subjects: 363

Group type: COMPARATOR
Intervention: Rote method
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Peer-generated-keyword group
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Subject generated keyword group
Number of subjects: 363

Group type: COMPARATOR
Intervention: Rote method (Experiment 2)
Number of subjects: 363
Study: 11413947

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (6-week duration)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 92
Study: 9250258

Group type: EXPERIMENTAL
Intervention: Nebulized heparin (20,000 units)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous heparin (25 U/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 8422173

Group type: EXPERIMENTAL
Intervention: Group A (surgical adjuvant chemotherapy with 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 800 mg/day of Futraful for one year)
Number of subjects: 2477

Group type: EXPERIMENTAL
Intervention: Group A (surgical adjuvant chemotherapy)
Number of subjects: 2477

Group type: COMPARATOR
Intervention: Group B (no treatment)
Number of subjects: 2477
Study: 3538870

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 2000
Study: 31490251

Group type: EXPERIMENTAL
Intervention: PECS II block with local anesthetic and surgical infiltration with 0.9% saline (PECS group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Surgical infiltration with local anesthetic and PECS II block with 0.9% saline (infiltration group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PECS II block
Number of subjects: 104

Group type: COMPARATOR
Intervention: Surgical infiltration with local anesthetic
Number of subjects: 104
Study: 31255174

Group type: EXPERIMENTAL
Intervention: StudyBuddy
Number of subjects: 44

Group type: COMPARATOR
Intervention: IVR
Number of subjects: 44
Study: 27673437

Group type: EXPERIMENTAL
Intervention: Surgical treatment (Endoscopic sinus surgery)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (non-CRS subjects)
Number of subjects: 187
Study: 25601535

Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab 0.3 mg
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Ranibizumab (both dosages)
Number of subjects: 759
Study: 23967634

Group type: EXPERIMENTAL
Intervention: Acupuncture + medication (Shugan Jianwei Anshen Decoction + acupuncture daily at specific points)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Western medicine (Deanxit, 1 tablet after getting up and after lunch)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Chinese medicine (Shugan Jianwei Anshen Decoction, 1 dose a day)
Number of subjects: 227
Study: 21698503

Group type: EXPERIMENTAL
Intervention: Adjuvant transcatheter arterial chemoembolization (TACE)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-TACE (control group)
Number of subjects: 125
Study: 18641208

Group type: EXPERIMENTAL
Intervention: Green tea consumption (4 cups or 960 mL per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black tea consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 0
Study: 16528207

Group type: EXPERIMENTAL
Intervention: 0.3T-DWI
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.5T-DWI
Number of subjects: 40
Study: 14519794

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement capsule
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement tablet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High carotenoid diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10896881

Group type: EXPERIMENTAL
Intervention: CCK octapeptide (CCK-8, 0.75 microgram infused over 10 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-A antagonist)
Number of subjects: 16
Study: 8849632

Group type: EXPERIMENTAL
Intervention: Verbal self-disclosure
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nondisclosure discussion
Number of subjects: 43
Study: 1613678

Group type: EXPERIMENTAL
Intervention: Nimodipine (4 x 60 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 32
Study: 6673899

Group type: EXPERIMENTAL
Intervention: Delta loop IUD
Number of subjects: 260

Group type: COMPARATOR
Intervention: Lippes loop D IUD
Number of subjects: 260
Study: 31238972

Group type: EXPERIMENTAL
Intervention: Specific acupressure (self-administered on five specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-specific acupressure (self-administered on five non-specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Number of subjects: 0
Study: 28086146

Group type: EXPERIMENTAL
Intervention: Group Psychoeducation (PEd)
Number of subjects: 304
Study: 26218933

Group type: EXPERIMENTAL
Intervention: mild (minimally invasive lumbar decompression)
Number of subjects: 300

Group type: COMPARATOR
Intervention: ESI (epidural steroid injections)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: mild
Number of subjects: 300

Group type: COMPARATOR
Intervention: ESI
Number of subjects: 300
Study: 23834353

Group type: EXPERIMENTAL
Intervention: Combination of low molecular weight heparin (LMWH) and prednisolone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) alone
Number of subjects: 52

Group type: COMPARATOR
Intervention: No drugs
Number of subjects: 52
Study: 21774287

Group type: EXPERIMENTAL
Intervention: Alcohol-based chlorhexidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 100
Study: 19186898

Group type: EXPERIMENTAL
Intervention: High-quality performance strategies
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-quality team charters and performance strategies
Number of subjects: 32

Group type: COMPARATOR
Intervention: Poor quality performance strategies
Number of subjects: 32
Study: 16888270

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA), 100 mg, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Number of subjects: 161
Study: 15220785

Group type: EXPERIMENTAL
Intervention: General anesthesia-thoracic epidural analgesia (TEA)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: General anesthesia-intrathecal analgesia (IT)
Number of subjects: 1846
Study: 11506109

Group type: EXPERIMENTAL
Intervention: Lubricated cuffs
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nonlubricated cuffs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lubricated cuffs in critically ill patients
Number of subjects: 45
Study: 8501369

Group type: EXPERIMENTAL
Intervention: Adrenaline infiltration
Number of subjects: 2

Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 2
Study: 3123606

Group type: EXPERIMENTAL
Intervention: R-(-)-deprenyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31498877

Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital-based phototherapy
Number of subjects: 0
Study: 29921891

Group type: EXPERIMENTAL
Intervention: Combined cyclophosphamide-based regimens (cyclophosphamide, cyclophosphamide + anthracycline, cyclophosphamide + ifosfamide + anthracycline)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Delayed complete resection for clinical group‐III patients
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Non-parameningeal clinical group‐I patients
Number of subjects: 553

Group type: COMPARATOR
Intervention: Anthracycline-based regimens
Number of subjects: 553

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy for non‐parameningeal group‐I patients
Number of subjects: 553
Study: 27230727

Group type: EXPERIMENTAL
Intervention: High-quality diet
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Moderate levels of physical activity
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Managerial/supervisory position
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 540